Biomarker Panel Articles & Analysis
13 news found
BioMark’s blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe’s screen-eligible population who are most likely to benefit from a CT scan. ...
The OncoDEEP Kit has been developed by expert oncologists to contain the most complete panel of biomarkers known to be associated with cancer therapies. The kit incorporates Twist Bioscience’s enrichment and library preparation solutions and has been optimized for the reliable analysis of somatic variants and translocations. ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug ...
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. ...
ByMiraDx
The focus of this strategic investment is the advancement of the HCC Panel toward commercial launch in the United States, transfer of the HCC Panel technology to Fosun Pharma’s diagnostic subsidiary for commercialization in China, and further development of pipeline tests for liver fibrosis and cholangiocarcinoma, the second most prevalent form of liver ...
The addition of these metabotypes to the previously published branch-chain amino acid dysregulation subtypes in the biomarker test panel under development by NeuroPointDX can now help identify approximately 41% of ASD-affected children as early as 18 months of age. ...
Glycotest Inc.’s HCC Panel is a unique algorithm-driven biomarker panel that takes advantage of the Company’s patented fucosylated biomarker technology. ...
Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. ...
Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. ...
Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. ...
Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. ...
With the help of Agilent's Mass Profiler Professional and Pathway Architect software, they hope to discover biomarker panels that could enable the development of future companion diagnostics. ...